Skip to content

Role and mechanism of ginseng-ling-white-jujutsu soup in chemotherapy-associated myasthenia gravis of intestinal cancer with spleen deficiency and dampness evidence

Role and mechanism of ginseng-ling-white-jujutsu soup in chemotherapy-associated myasthenia gravis of intestinal cancer with spleen deficiency and dampness evidence

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000854
Enrollment
Unknown
Registered
2024-12-22
Start date
2024-12-31
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer sarcopenia

Interventions

experimental group:Oral Ginseng and Atractylodes Macrocephalae Soup
control subjects:No Ginseng and Atractylodis Macrocephalae.

Sponsors

Shanghai Tongren Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) Postoperative pathology confirmed the diagnosis of colon cancer and supplemented with chemotherapy; 2) Meet the diagnostic criteria of postoperative chemotherapy XELOX program and spleen deficiency and dampness syndrome of colon cancer: primary symptoms: poor appetite tiredness fatigue gastrointestinal and abdominal distension or pain vomiting loose stools or diarrhea; secondary symptoms: yellowish color head and body drowsiness fatigue and laziness bland mouth and no thirst. Diagnosis can be made if there are two primary symptoms and one secondary symptom or one primary symptom and two secondary symptoms; 3) Meet the diagnostic criteria of sarcopenia: according to the latest diagnostic criteria of AWGS2019 muscle mass reduction is represented by ASMI <7.0kg/m2 for men and ASMI <5.7kg/m2 for women; muscle strength reduction is represented by grip strength <28kg for men and grip strength <18kg for women; and somatic function reduction is represented by 6m walking speed <1.0m/s. The diagnosis of sarcopenia can be fulfilled by a decrease in muscle mass with a decrease in muscle strength and/or a decrease in somatic function.

Exclusion criteria

Exclusion criteria: 1) preoperative radiotherapy or other immunotherapy etc.; 2) with heart liver kidney and other important organs failure. 2) Patients with heart liver kidney and other important organ failure; 3) Patients with physical deformities that cannot be tested for muscle strength or physical fitness.

Design outcomes

Primary

MeasureTime frame
6-meter walking speed;Muscle Strength;Appendicularskeletalmusclemass;

Secondary

MeasureTime frame
BMI;Body fat percentage;

Countries

China

Contacts

Public ContactJin Huang

Shanghai Tongren Hospital

342647302@qq.com15256071178

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026